[Multimodal laryngeal preservation: current data-based opinion]
- PMID: 22282007
- DOI: 10.1007/s00106-011-2416-7
[Multimodal laryngeal preservation: current data-based opinion]
Abstract
This article presents the current data and discussion on multimodal laryngeal preservation strategies in advanced laryngeal/hypopharyngeal carcinoma. Principally a distinction is made between simultaneous and induction chemoradiation protocols. In terms of late toxicity and related functional limitations, induction protocols are far superior to simultaneous platinum-based chemoradiation. Currently, the individual response to the first cycle of (short) induction chemotherapy appears to be the most reliable clinical marker for making treatment decisions, and this is under clinical investigation. No standard multimodal therapeutic alternative to laryngectomy exists; therefore, at this time multimodal strategies should only be carried out within the framework of clinical trials.
Similar articles
-
[Recent advances in the treatment of laryngeal and hypopharyngeal carcinoma].HNO. 2012 Jan;60(1):6-18. doi: 10.1007/s00106-011-2422-9. HNO. 2012. PMID: 22282006 German.
-
Severe late dysphagia after multimodal treatment of stage III/IV laryngeal and hypopharyngeal cancer.Jpn J Clin Oncol. 2020 Feb 17;50(2):185-192. doi: 10.1093/jjco/hyz158. Jpn J Clin Oncol. 2020. PMID: 31711185
-
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.Ann Oncol. 2018 Oct 1;29(10):2105-2114. doi: 10.1093/annonc/mdy332. Ann Oncol. 2018. PMID: 30412221 Clinical Trial.
-
[Squamous cell carcinoma of the hypopharynx and larynx: evidence-based care].Bull Cancer. 2014 May 1;101(5):438-44. doi: 10.1684/bdc.2014.1945. Bull Cancer. 2014. PMID: 24886894 Review. French.
-
[Organ preservation in advanced laryngeal/hypopharyngeal carcinoma: lessons from the DeLOS-II trial].HNO. 2020 Sep;68(9):648-656. doi: 10.1007/s00106-020-00890-5. HNO. 2020. PMID: 32468135 Review. German.
Cited by
-
Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival.Front Immunol. 2025 Jan 15;15:1473897. doi: 10.3389/fimmu.2024.1473897. eCollection 2024. Front Immunol. 2025. PMID: 39882242 Free PMC article.
-
Laryngeal Preservation Approaches: Considerations for New Selection Criteria Based on the DeLOS-II Trial.Front Oncol. 2019 Jul 10;9:625. doi: 10.3389/fonc.2019.00625. eCollection 2019. Front Oncol. 2019. PMID: 31355142 Free PMC article. Review.
-
Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance.Br J Cancer. 2014 Jan 21;110(2):479-88. doi: 10.1038/bjc.2013.700. Epub 2013 Nov 21. Br J Cancer. 2014. PMID: 24263061 Free PMC article.
-
The importance of stem cell engineering in head and neck oncology.Biotechnol Lett. 2016 Oct;38(10):1665-72. doi: 10.1007/s10529-016-2163-7. Epub 2016 Jun 24. Biotechnol Lett. 2016. PMID: 27341837 Free PMC article. Review.
-
hTERT gene knockdown enhances response to radio- and chemotherapy in head and neck cancer cell lines through a DNA damage pathway modification.Sci Rep. 2018 Apr 13;8(1):5949. doi: 10.1038/s41598-018-24503-y. Sci Rep. 2018. PMID: 29654294 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources